Bioactivity Focus of α-Cyano-4-hydroxycinnamic Acid (CHCA) Leads to Effective Multifunctional Aldose Reductase Inhibitors

Overview

Journal Sci Rep

Specialty Science

Date 2016 Apr 26

PMID 27109517

Citations 4

Authors

Laitao Zhang

Yi-Fang Li

Sheng Yuan

Shijie Zhang

Huanhuan Zheng

Jie Liu

Pinghua Sun

Yijun Gu

Hiroshi Kurihara

Rong-Rong He

Heru Chen

Affiliations

Soon will be listed here.

Abstract

Bioactivity focus on α-cyano-4-hydroxycinnamic acid (CHCA) scaffold results in a small library of novel multifunctional aldose reductase (ALR2) inhibitors. All the entities displayed good to excellent inhibition with IC50 72-405 nM. (R,E)-N-(3-(2-acetamido-3-(benzyloxy)propanamido)propyl)-2-cyano-3-(4-hydroxy phenyl)acrylamide (5f) was confirmed as the most active inhibitor (IC50 72.7 ± 1.6 nM), and the best antioxidant. 5f bound to ALR2 with new mode without affecting the aldehyde reductase (ALR1) activity, implicating high selectivity to ALR2. 5f was demonstrated as both an effective ALR2 inhibitor (ARI) and antioxidant in a chick embryo model of hyperglycemia. It attenuated hyperglycemia-induced incidence of neural tube defects (NTD) and death rate, and significantly improved the body weight and morphology of the embryos. 5f restored the expression of paired box type 3 transcription factor (Pax3), and reduced the hyperglycemia-induced increase of ALR2 activity, sorbitol accumulation, and the generation of ROS and MDA to normal levels. All the evidences support that 5f may be a potential agent to treat diabetic complications.

Citing Articles

Compounds with Antioxidant Activity, and Inhibition Potential against Tyrosinase, Melanin, Hyaluronidase, Elastase, and Collagenase.

Apaza Ticona L, Sanchez Sanchez-Corral J, Diaz-Guerra Martin C, Calderon Jimenez S, Lopez Gonzalez A, Thiebaut Estrada C Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065787 PMC: 11280343. DOI: 10.3390/ph17070937.

Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.

Iyer S, Sam F, DiPrimio N, Preston G, Verheijen J, Murthy K Dis Model Mech. 2019; 12(11).

PMID: 31636082 PMC: 6899038. DOI: 10.1242/dmm.040584.

Yeast Models of Phosphomannomutase 2 Deficiency, a Congenital Disorder of Glycosylation.

Lao J, DiPrimio N, Prangley M, Sam F, Mast J, Perlstein E G3 (Bethesda). 2018; 9(2):413-423.

PMID: 30530630 PMC: 6385982. DOI: 10.1534/g3.118.200934.

Conformational Differentiation of α-Cyanohydroxycinnamic Acid Isomers: A Raman Spectroscopic Study.

Vedad J, Domaradzki M, Mojica E, Chang E, Profit A, Desamero R J Raman Spectrosc. 2017; 48(10):1282-1288.

PMID: 29225410 PMC: 5720387. DOI: 10.1002/jrs.5209.

References

Matsumoto T, Ono Y, Kurono M, Kuromiya A, Nakamura K, Bril V . Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats. J Pharmacol Sci. 2008; 107(3):231-7. DOI: 10.1254/jphs.08061fp. View

Newman D, Cragg G . Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod. 2012; 75(3):311-35. PMC: 3721181. DOI: 10.1021/np200906s. View

Lipinski C, Aldinger C, Beyer T, Bordner J, Burdi D, Bussolotti D . Hydantoin bioisosteres. In vivo active spiro hydroxy acetic acid aldose reductase inhibitors. J Med Chem. 1992; 35(12):2169-77. DOI: 10.1021/jm00090a004. View

Obrosova I, Pacher P, Szabo C, Zsengeller Z, Hirooka H, Stevens M . Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications. Diabetes. 2004; 54(1):234-42. PMC: 2756473. DOI: 10.2337/diabetes.54.1.234. View

Veeresham C, Rama Rao A, Asres K . Aldose reductase inhibitors of plant origin. Phytother Res. 2013; 28(3):317-33. DOI: 10.1002/ptr.5000. View

Smar M, Ares J, Nakayama T, Itabe H, Kador P, Miller D . Selective irreversible inhibitors of aldose reductase. J Med Chem. 1992; 35(6):1117-20. DOI: 10.1021/jm00084a017. View

Prior R, Hoang H, Gu L, Wu X, Bacchiocca M, Howard L . Assays for hydrophilic and lipophilic antioxidant capacity (oxygen radical absorbance capacity (ORAC(FL))) of plasma and other biological and food samples. J Agric Food Chem. 2003; 51(11):3273-9. DOI: 10.1021/jf0262256. View

Zheng H, Luo C, Chen H, Lin J, Ye C, Mao S . Xanthones from Swertia mussotii as multitarget-directed antidiabetic agents. ChemMedChem. 2014; 9(7):1374-7. DOI: 10.1002/cmdc.201300507. View

Sturm K, Levstik L, Demopoulos V, Kristl A . Permeability characteristics of novel aldose reductase inhibitors using rat jejunum in vitro. Eur J Pharm Sci. 2006; 28(1-2):128-33. DOI: 10.1016/j.ejps.2006.01.006. View

10.

Sethi A, Lees D, Douthwaite J, Dawnay A, Corder R . Homocysteine-induced endothelin-1 release is dependent on hyperglycaemia and reactive oxygen species production in bovine aortic endothelial cells. J Vasc Res. 2006; 43(2):175-83. DOI: 10.1159/000090947. View

11.

Nakahara M, Miyata K, Otani S, Miyai T, Nejima R, Yamagami S . A randomised, placebo controlled clinical trial of the aldose reductase inhibitor CT-112 as management of corneal epithelial disorders in diabetic patients. Br J Ophthalmol. 2005; 89(3):266-8. PMC: 1772556. DOI: 10.1136/bjo.2004.049841. View

12.

Vauzour D, Corona G, Spencer J . Caffeic acid, tyrosol and p-coumaric acid are potent inhibitors of 5-S-cysteinyl-dopamine induced neurotoxicity. Arch Biochem Biophys. 2010; 501(1):106-11. DOI: 10.1016/j.abb.2010.03.016. View

13.

Wirasathien L, Pengsuparp T, Suttisri R, Ueda H, Moriyasu M, Kawanishi K . Inhibitors of aldose reductase and advanced glycation end-products formation from the leaves of Stelechocarpus cauliflorus R.E. Fr. Phytomedicine. 2006; 14(7-8):546-50. DOI: 10.1016/j.phymed.2006.09.001. View

14.

Sestanj K, Bellini F, Fung S, Abraham N, Treasurywala A, HUMBER L . N-[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]- N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor. J Med Chem. 1984; 27(3):255-6. DOI: 10.1021/jm00369a003. View

15.

Sanchez-Ferras O, Bernas G, Laberge-Perrault E, Pilon N . Induction and dorsal restriction of Paired-box 3 (Pax3) gene expression in the caudal neuroectoderm is mediated by integration of multiple pathways on a short neural crest enhancer. Biochim Biophys Acta. 2014; 1839(7):546-58. DOI: 10.1016/j.bbagrm.2014.04.023. View

16.

Giles G, Jacob C . Reactive sulfur species: an emerging concept in oxidative stress. Biol Chem. 2002; 383(3-4):375-88. DOI: 10.1515/BC.2002.042. View

17.

Vajragupta O, Boonchoong P, Berliner L . Manganese complexes of curcumin analogues: evaluation of hydroxyl radical scavenging ability, superoxide dismutase activity and stability towards hydrolysis. Free Radic Res. 2004; 38(3):303-14. DOI: 10.1080/10715760310001643339. View

18.

Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M . Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care. 2006; 29(7):1538-44. DOI: 10.2337/dc05-2370. View

19.

Asano T, Saito Y, Kawakami M, Yamada N . Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients. J Diabetes Complications. 2002; 16(2):133-8. DOI: 10.1016/s1056-8727(01)00175-1. View

20.

Oyama T, Miyasita Y, Watanabe H, Shirai K . The role of polyol pathway in high glucose-induced endothelial cell damages. Diabetes Res Clin Pract. 2006; 73(3):227-34. DOI: 10.1016/j.diabres.2006.02.010. View